Tailored and G-CSF supported 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer - : a phase II study using a novel dosing strategy
Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Johan Ahlgren(Uppsala University), Carl Blomqvist(University of Helsinki), Peter Nygren(Uppsala University), Gunnar Åström(Uppsala University), Kenneth Villman(Örebro University Hospital)
Unknown
January 1, 2003
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k